First-line immunosuppression in neuromuscular diseases
| Autor: | Michael A Foster, Michael PT Lunn, Aisling S Carr |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Practical Neurology. :pn-2023 |
| ISSN: | 1474-7766 1474-7758 |
| Popis: | Autoimmune neuromuscular diseases are common and often treatable causes for peripheral nervous system dysfunction. If not optimally managed, they result in meaningful impairments and disability. The treating neurologist should aim to maximise clinical recovery with minimal iatrogenic risk. This requires careful patient and medication selection, appropriate counselling and close monitoring of clinical efficacy and safety. Here, we summarise our consensus departmental approach to first-line immunosuppression in neuromuscular diseases. We combine multispecialty evidence and expertise with a focus on autoimmune neuromuscular diseases to create guidance on starting, dosing and monitoring for toxic effects of the commonly used drugs. These include corticosteroids, steroid-sparing agents and cyclophosphamide. We also provide efficacy monitoring advice, as clinical response informs dosage and drug choice. The principles of this approach could be applied across much of the spectrum of immune-mediated neurological disorders where there is significant therapeutic crossover. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|